Printer Friendly

C O R R E C T I O N TO CAMBRIDGE BIOTECH CORPORATION ACQUIRES MINORITY STAKE IN ADI.

 /C O R R E C T I O N -- CAMBRIDGE BIOTECH/
 In NY007 -- Cambridge Biotech Corporation acquires minority stake in


ADI -- moved earlier today, the phone number in the contact line for Peter P. Hartman, VP-finance and CFO of Cambridge Biotech, should be 508-797-5777 sted of 507-797-5777 as originally transmitted.
 -0- 4/2/92 C NY007
 (CBCX BIOMF) CO: Cambridge Biotech Corporation; ADI Diagnostics Inc.; Biomira Inc. ST: Massachusetts, Ontario IN: MTC SU: TNM


GK-TS -- NY007A -- 4224 04/02/92 09:12 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 2, 1992
Words:84
Previous Article:THERMO PROCESS SYSTEMS RECEIVES $2.2M ORDER FROM TIMKEN
Next Article:AGENCY RENT-A-CAR, INC. SHIFTS INTO HIGH GEAR REPORTS EPS UP 28 PERCENT
Topics:


Related Articles
CAMBRIDGE BIOTECH REPORTS 1991 RESULTS OF $0.02 PER SHARE FOR YEAR
BIOMIRA CONSOLIDATES MANUFACTURING & MARKETING OF CANCER DIAGNOSTIC KITS IN ADI DIAGNOSTICS; CAMBRIDGE BIOTECH ACQUIRES MINORITY STAKE IN ADI
CAMBRIDGE BIOTECH CORPORATION SIGNS INTENT TO ACQUIRE MINORITY STAKE IN IMMUCELL CORPORATION
BIOMIRA INC. PURCHASES REMAINING SHARES OF ADI FROM CAMBRIDGE BIOTECH CORPORATION
DCA ANNOUNCES SELECT COMM SERVER WITH PC ROUTER SUPPORT
CompuServe, Golden CommPass Team Up To Reach OS-2 Market
Compuware Delivers Enhanced Enterprise Test Data Management Solution; Compuware File-AID/CS 3.0 Offers Rich Data-Management Functionality With...
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.
Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters